We have collected information about Quinone Bioreductive Prodrugs As Delivery Agents for you. Follow the links to find out details on Quinone Bioreductive Prodrugs As Delivery Agents.
http://www.eurekaselect.com/openurl/content.php?genre=article&issn=1567-2018&volume=1&issue=4&spage=345
Keywords:quinone, indolequinone, benzoquinone, naphthoquinone, bioreductive agents, hypoxia-selectivity, delivery agents, oxidoreductive enzymes. Abstract: Quinone bioreductive prodrugs were developed to target the hypoxic or the reductase- rich population of solid tumours. The mechanism of their selective activation is based on their ability ...Author: Mohammed Jaffar, Nathalie Abou-Zeid, Li Bai, Ibrahim Mrema, Ian Robinson, Richard Tanner, Ian J. Str...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3935009/
To this end, a number of bioreductive prodrugs have been designed in the last three decades. Although several hypoxia-selective prodrugs have progressed to clinical trials, none have yet been approved for clinical use. This partly reflects some of the many challenges and limitations that have come to light during the development of these agents.Author: Christopher P. Guise, Alexandra M. Mowday, Amir Ashoorzadeh, Ran Yuan, Wan-Hua Lin, Dong-Hai Wu, Jef...
https://www.sciencedirect.com/science/article/pii/S0169409X01002289
Dec 17, 2001 · They are prodrugs, that are reductively activated (catalysed by reductive enzymes) to afford their active (toxic) species. More recently, bioreductive delivery agents that ‘release’ a therapeutic entity preferentially under hypoxic conditions have also been developed to target hypoxia, not only in tumours, but also in a host of other diseases.Author: Mohammed Jaffar, Kaye J Williams, Ian J Stratford
https://www.sciencedirect.com/science/article/pii/S0223523417302143
The enzyme NQO1 is a potential target for selective cancer therapy due to its overexpression in certain hypoxic tumors. A series of prodrugs possessing a variety of cytotoxic diterpenoids (oridonin and its analogues) as the leaving groups activated by NQO1 were synthesized by functionalization of 3-(hydroxymethyl)indolequinone, which is a good substrate of NQO1.Author: Shengtao Xu, Hong Yao, Lingling Pei, Mei Hu, Dahong Li, Dahong Li, Yangyi Qiu, Guangyu Wang, Liang W...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4147050/
Jul 09, 2014 · Prodrugs are widely used in the targeted delivery of cytotoxic compounds to cancer cells. To date, targeted prodrugs for cancer therapy have achieved great diversity in terms of target selection, activation chemistry, as well as size and physicochemical nature of the prodrug.Author: Irene Giang, Erin L. Boland, Erin L. Boland, Gregory M. K. Poon
https://www.researchgate.net/publication/12270790_Clinical_applications_of_quinone-containing_alkylating_agents
Quinone-containing alkylating agents are a class of chemical agents that have received considerable interest as anticancer drugs. These agents contain a quinone moiety that can be reduced and an ...
https://mct.aacrjournals.org/content/6/12/3122
Dec 01, 2007 · NAD(P)H:quinone oxidoreductase-1 (NQO1) is a potential target for therapeutic intervention but attempts to exploit NQO1 using quinone-based bioreductive prodrugs have been largely compromised by toxicity to organs that inherently express high levels of NQO1. In an attempt to circumvent this problem, this study describes the development of a tripartite quinone-based drug delivery …Author: Milene Volpato, Nathalie Abou-Zeid, Richard W Tanner, Lee T Glassbrook, James Taylor, Ian J Stratfor...
https://pubs.acs.org/doi/10.1021/jm000179o
A series of naphthoquinone and benzimidazolequinone phosphorodiamidates has been synthesized and studied as potential cytotoxic prodrugs activated by DT-diaphorase. Reduction of the quinone moiety in the target compounds was expected to provide a pathway for expulsion of the phosphoramide mustard alkylating agent. All of the compounds synthesized were excellent substrates for purified human DT ...Author: Carolee Flader, Jiwen Liu, Richard F. Borch
https://www.researchgate.net/publication/6314180_Hypoxia-driven_elimination_of_thiopurines_from_their_nitrobenzyl_prodrugs
This technology platform is currently being used to design/identify, and synthesise novel quinone bioreductive delivery agents to target cancer and other diseases where hypoxia and/or reductive ...
https://www.researchgate.net/scientific-contributions/38349036_Mohammed_Jaffar
no NAD(P)H:quinone oxidoreductase-1 (NQO1) is a potential target for therapeutic intervention but attempts to exploit NQO1 using quinone-based bioreductive prodrugs have been largely compromised ...
Searching for Quinone Bioreductive Prodrugs As Delivery Agents?
You can just click the links above. The data is collected for you.
